Patents by Inventor Anne-Laure Flamar

Anne-Laure Flamar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins comprising an anti-CD40 antibody and cancer antigens
    Patent number: 11806390
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: November 7, 2023
    Assignee: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Methods and compositions for treating and preventing HIV
    Patent number: 11219683
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: January 11, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE M{circumflex over (D)}DICALE (INSERM), UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BAYLOR RESEARCH INSTITUTE
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • FUSION PROTEINS COMPRISING AN ANTI-CD40 ANTIBODY AND CANCER ANTIGENS
    Publication number: 20210308242
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: April 12, 2021
    Publication date: October 7, 2021
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard ZURAWSKI, Jacques F. Banchereau, Anne-Laure FLAMAR, Peter KLUCAR, Keiko AKAGAWA, Sandra ZURAWSKI, SangKon OH
  • FUSION PROTEINS COMPRISING AN ANTI-CD40 ANTIBODY AND HIV ANTIGENIC PEPTIDES
    Publication number: 20210221904
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 22, 2021
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard ZURAWSKI, Jacques F. Banchereau, Anne-Laure FLAMAR, Yves Levy, Monica Montes
  • Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides
    Patent number: 10988544
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: April 27, 2021
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Fusion proteins comprising an anti-CD40 antibody and cancer antigens
    Patent number: 10980869
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 20, 2021
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING HIV
    Publication number: 20200316191
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Yves LEVY, Gerard ZURAWSKI, Sandra ZURAWSKI, Anne-Laure FLAMAR
  • Methods and compositions for treating and preventing HIV
    Patent number: 10722572
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: July 28, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, BAYLOR RESEARCH INSTITUTE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Methods and compositions for treating and preventing HIV
    Patent number: 10610585
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: April 7, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Baylor Research Institute, Universite Paris Est Creteil Val De Marne, Assistance Publique Hopitaux de Paris
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING HIV
    Publication number: 20200101152
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Application
    Filed: December 10, 2019
    Publication date: April 2, 2020
    Inventors: Yves LEVY, Gerard ZURAWSKI, Sandra ZURAWSKI, Anne-Laure FLAMAR
  • Methods and Compositions for Treating and Preventing HIV
    Publication number: 20190184008
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Application
    Filed: September 25, 2018
    Publication date: June 20, 2019
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • ANTIGEN PRESENTING CELL TARGETED VACCINES
    Publication number: 20180094071
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: October 18, 2017
    Publication date: April 5, 2018
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES
    Publication number: 20180000916
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 4, 2018
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon OH
  • Antigen presenting cell targeted anti-viral vaccines
    Patent number: 9416186
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: August 16, 2016
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • MULTIVARIABLE ANTIGENS COMPLEXED WITH TARGETING HUMANIZED MONOCLONAL ANTIBODY
    Publication number: 20160031988
    Abstract: The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 4, 2016
    Inventors: Gerard Zurawski, Anne-Laure Flamar, Eynav Klechevsky
  • ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES
    Publication number: 20160022792
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: August 6, 2015
    Publication date: January 28, 2016
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
    Patent number: 9234040
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 12, 2016
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • ANTIGEN PRESENTING CELL TARGETED VACCINES
    Publication number: 20150299329
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: January 30, 2015
    Publication date: October 22, 2015
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
    Patent number: 9109011
    Abstract: The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: August 18, 2015
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Anne-Laure Flamar, Amanda Cobb, Holly Mead, Monica Montes, Sandra Zurawski, SangKon Oh
  • Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
    Patent number: 9102730
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 11, 2015
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar